These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 39067002)

  • 1. Synthesis of scaberol C amino acid ester derivatives with anti-cancer activity.
    Li CL; Han Z; Luo DY; Ren H; Ye L; Yao GD; Liu QB
    J Asian Nat Prod Res; 2024 Jul; ():1-18. PubMed ID: 39067002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and biological evaluation of 4-(2-fluorophenoxy)-7-methoxyquinazoline derivatives as dual EGFR/c-Met inhibitors for the treatment of NSCLC.
    Tang S; Sun C; He X; Gan W; Wang L; Qiao D; Guan X; Xu S; Zheng P; Zhu W
    Eur J Med Chem; 2024 Jan; 263():115939. PubMed ID: 37984296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and biological evaluation of 2,3-dihydro-[1,4]dioxino[2,3-f]quinazoline derivatives as EGFR inhibitors.
    Qin X; Yang L; Liu P; Yang L; Chen L; Hu L; Jiang M
    Bioorg Chem; 2021 May; 110():104743. PubMed ID: 33714020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and Synthesis of New Hydantoin Acetanilide Derivatives as Anti-NSCLC Targeting EGFR
    Hassanin MA; Mustafa M; Abourehab MAS; Hassan HA; Aly OM; Beshr EAM
    Pharmaceuticals (Basel); 2022 Jul; 15(7):. PubMed ID: 35890154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and Anticancer Activity of Novel Indole Derivatives as Dual EGFR/SRC Kinase Inhibitors.
    Olgen S; Kaleli SNB; Karaca BT; Demirel UU; Bristow HK
    Curr Med Chem; 2024; 31(24):3798-3817. PubMed ID: 37365789
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Thongsom S; Racha S; Ei ZZ; Petsri K; Aksorn N; Chamni S; Panpuang V; Zou H; Chanvorachote P
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computational and Synthetic approach with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S triple mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC).
    Karnik KS; Sarkate AP; Tiwari SV; Azad R; Burra PVLS; Wakte PS
    Bioorg Chem; 2021 Feb; 107():104612. PubMed ID: 33476869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, biological assessment and molecular modeling studies of novel imidazothiazole-thiazolidinone hybrids as potential anticancer and anti-inflammatory agents.
    Kamboj P; Anjali ; Imtiyaz K; Rizvi MA; Nath V; Kumar V; Husain A; Amir M
    Sci Rep; 2024 Apr; 14(1):8457. PubMed ID: 38605072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
    Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
    Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
    Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
    Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and biological evaluation of novel quinoline derivatives as small molecule mutant EGFR inhibitors targeting resistance in NSCLC: In vitro screening and ADME predictions.
    Kardile RA; Sarkate AP; Lokwani DK; Tiwari SV; Azad R; Thopate SR
    Eur J Med Chem; 2023 Jan; 245(Pt 1):114889. PubMed ID: 36375337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of miR-203 increases the sensitivity of NSCLC A549/H460 cell lines to cisplatin by targeting Dickkopf-1.
    Cheng R; Lu C; Zhang G; Zhang G; Zhao G
    Oncol Rep; 2017 Apr; 37(4):2129-2136. PubMed ID: 28350100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Falnidamol and cisplatin combinational treatment inhibits non-small cell lung cancer (NSCLC) by targeting DUSP26-mediated signal pathways.
    Cui Z; Li D; Zhao J; Chen K
    Free Radic Biol Med; 2022 Apr; 183():106-124. PubMed ID: 35278641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and antitumor activity of 4-arylamine substituted pyrimidine derivatives as noncovalent EGFR inhibitors overcoming C797S mutation.
    Zuo Y; Long Z; Li R; Le Y; Zhang S; He H; Yan L
    Eur J Med Chem; 2024 Feb; 265():116106. PubMed ID: 38169271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mechanism of n-butanol fraction of Wenxia Formula combining with gefitinib in treating non-small cell lung cancer based on network pharmacology and in vitro experiment].
    Chen RJ; Bi QY; Shi JM; Zhong J; Han JT; Ji XM
    Zhongguo Zhong Yao Za Zhi; 2024 Jan; 49(2):471-486. PubMed ID: 38403323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and docking studies of quinazoline analogues bearing aryl semicarbazone scaffolds as potent EGFR inhibitors.
    Tu Y; Wang C; Xu S; Lan Z; Li W; Han J; Zhou Y; Zheng P; Zhu W
    Bioorg Med Chem; 2017 Jun; 25(12):3148-3157. PubMed ID: 28428040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Niflumic Acid Derivatives as EGFR Inhibitors: Design, Synthesis,
    Yaseen YS; Mahmood AAR; Abbas AH; Shihab WA; Tahtamouni LH
    Med Chem; 2023; 19(5):445-459. PubMed ID: 36537605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemistry of Renieramycins. Part 19: Semi-Syntheses of 22-
    Chamni S; Sirimangkalakitti N; Chanvorachote P; Suwanborirux K; Saito N
    Mar Drugs; 2020 Aug; 18(8):. PubMed ID: 32785022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel 2-(5-Aryl-4,5-Dihydropyrazol-1-yl)thiazol-4-One as EGFR Inhibitors: Synthesis, Biological Assessment and Molecular Docking Insights.
    Al-Warhi T; El Kerdawy AM; Said MA; Albohy A; Elsayed ZM; Aljaeed N; Elkaeed EB; Eldehna WM; Abdel-Aziz HA; Abdelmoaz MA
    Drug Des Devel Ther; 2022; 16():1457-1471. PubMed ID: 35607598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, Synthesis,
    Matada GSP; Abbas N; Dhiwar PS; Basu R; Devasahayam G
    Anticancer Agents Med Chem; 2021; 21(4):451-461. PubMed ID: 32698735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.